Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q8TCT6
UPID:
SPPL3_HUMAN
Alternative names:
Intramembrane protease 2; Presenilin homologous protein 1; Presenilin-like protein 4
Alternative UPACC:
Q8TCT6; Q3MJ04; Q8TAU4; Q96DD9
Background:
Signal peptide peptidase-like 3, also known as Intramembrane protease 2, Presenilin homologous protein 1, and Presenilin-like protein 4, is a crucial intramembrane-cleaving aspartic protease (I-CLiP). It specializes in cleaving type II membrane protein substrates near their luminal transmembrane domain boundaries. This protein plays a pivotal role in the proteolytic release and secretion of active site-containing ectodomains of various glycan-modifying enzymes, significantly impacting cellular glycosylation processes.
Therapeutic significance:
Understanding the role of Signal peptide peptidase-like 3 could open doors to potential therapeutic strategies. Its involvement in cellular glycosylation and proteolytic processes makes it a promising target for drug discovery, aiming to modulate its activity for therapeutic benefits.